Heart disease develops gradually, over decades, through a process that begins with damage to the inner lining of your arteries and ends with blockages that restrict blood flow to your heart. The earliest signs of this process, fatty streaks inside artery walls, have been found in children as young as two years old. By the time symptoms appear, the disease has typically been building for 20 to 40 years.
It Starts With Damage to the Artery Lining
Your arteries are lined with a thin layer of cells called the endothelium. This lining acts as a barrier, keeping blood flowing smoothly and preventing harmful substances from penetrating the artery wall. When that lining gets damaged or starts to malfunction, it becomes the first domino in a long chain of events.
Several forces can cause this initial damage. High blood pressure physically batters artery walls, creating a fatiguing effect on the structural proteins that keep arteries flexible. Areas where blood flow is turbulent or slow, like bends and branch points in arteries, are especially vulnerable. The low flow in these regions changes the shape and behavior of the lining cells, making those spots prone to disease even in otherwise healthy people. High blood sugar, smoking, and chronic inflammation all compound the damage.
How Cholesterol Gets Trapped in the Wall
Once the artery lining is compromised, LDL cholesterol particles begin slipping through it and getting trapped in the space underneath. There, they undergo a chemical change called oxidation, similar to how metal rusts when exposed to air. This transforms them from normal blood components into something the body treats as a threat.
Your immune system responds by sending white blood cells called monocytes to the site. These cells burrow into the artery wall, mature into macrophages (a type of immune cell that engulfs foreign material), and begin swallowing the oxidized LDL. The problem is that macrophages are poorly equipped to handle large amounts of cholesterol. They gorge themselves until they become bloated, cholesterol-stuffed cells known as foam cells. Clusters of foam cells form what pathologists call fatty streaks, the earliest visible sign of atherosclerosis.
Autopsy studies of young people paint a striking picture of how early this begins. In the Bogalusa Heart Study, which examined arteries in people aged 2 to 39, about 50% of children between ages 2 and 15 already had fatty streaks in their coronary arteries. By ages 21 to 39, that number climbed to 85%. Japanese autopsy data found fatty streaks in the aortas of 29% of infants under one year old.
From Fatty Streak to Fibrous Plaque
Fatty streaks are reversible. The transition to a more permanent, structural plaque is what locks in the disease. As foam cells accumulate and die, they release their cholesterol payload into the artery wall, forming a growing pool of lipid debris. The activated immune cells and damaged lining cells release chemical signals that attract smooth muscle cells from deeper layers of the artery. These muscle cells migrate inward, multiply, and begin producing a tough structural matrix, essentially building a cap of fibrous tissue over the growing lipid pool.
The result is a fibrous plaque: a mound inside the artery wall with a tough outer shell and a soft, fatty core. Over time, the core fills with oxidized cholesterol, cholesterol crystals, dead cells, and other debris, forming what’s called a necrotic core. The plaque may also develop patches of calcium deposits, similar to how bone forms. In the Bogalusa study, these raised fibrous plaques were present in 8% of people aged 2 to 15 and jumped to 69% in those aged 26 to 39.
Inflammation Drives the Process Forward
Atherosclerosis is not simply a plumbing problem of cholesterol clogging pipes. It is fundamentally an inflammatory disease, and inflammation is what keeps the process accelerating once it starts.
Immune cells at the edges of plaques release signaling molecules called cytokines that recruit even more immune cells and amplify the damage. Two markers in particular, IL-6 and C-reactive protein (CRP), are strongly linked to heart disease risk. IL-6 drives inflammation at the plaque site, while CRP, produced mainly in the liver in response to IL-6, travels through the blood and amplifies the immune response further. CRP has been found directly inside plaques, sitting alongside lipids and immune cells in the artery wall, where it actively promotes further damage. Elevated CRP levels are an independent predictor of heart attack, stroke, and peripheral artery disease.
What Makes a Plaque Dangerous
Not all plaques are equally threatening. A large plaque that narrows an artery by 70% might cause chest pain during exercise but never trigger a heart attack. Meanwhile, a smaller plaque with the wrong internal structure can rupture without warning and cause a fatal event. The distinction between stable and vulnerable plaques is one of the most important concepts in understanding heart disease.
Stable plaques have a thick fibrous cap, plenty of smooth muscle cells maintaining that cap, and heavy calcification. They tend to narrow the artery gradually, and the heart often adapts by developing collateral blood vessels around the blockage.
Vulnerable plaques look very different. They have a thin fibrous cap (less than 65 micrometers thick), a large necrotic core, heavy infiltration of inflammatory cells, and only scattered spots of calcification rather than dense sheets of it. The inflammatory cells at the edges of these plaques release enzymes that actively digest the fibrous cap, making it progressively thinner and weaker. When the cap finally gives way, the contents of the necrotic core spill into the bloodstream and trigger a massive blood clot. If that clot blocks the artery, the result is a heart attack. Sometimes the clot forms even without a full rupture, when the surface lining erodes and exposes the underlying tissue to flowing blood.
How Diabetes Accelerates the Process
Persistently high blood sugar speeds up every stage of atherosclerosis through a specific chemical process. Glucose molecules in the blood react with proteins, fats, and other molecules to form compounds called advanced glycation end products, or AGEs. This is a slow, non-enzymatic reaction that intensifies the longer blood sugar stays elevated, which is why people with a long history of diabetes accumulate the most AGEs.
AGEs cause damage in two ways. First, they directly alter the structure of LDL cholesterol, making it more likely to penetrate artery walls and trigger plaque formation. Second, they bind to receptors on cells throughout the artery wall, triggering inflammatory and clotting responses. AGEs also interfere with the body’s system for removing excess cholesterol from cells. They suppress the transport proteins that shuttle cholesterol out of macrophages and back to the liver, essentially trapping more cholesterol inside the artery wall. Autopsy studies confirm the connection: hyperglycemia is strongly associated with the extent of both fatty streaks and raised lesions in the coronary arteries and aorta.
Genetic Factors That Raise Risk Independently
One genetic factor stands out for its outsized role in heart disease: lipoprotein(a), often written as Lp(a). This is a particle that looks like LDL cholesterol but has an extra protein attached to it. Your Lp(a) level is almost entirely determined by your genes and doesn’t respond much to diet or exercise.
Lp(a) is estimated to be about six times more atherogenic than regular LDL cholesterol. It contributes to heart disease through mechanisms that go beyond its cholesterol content. It carries oxidized fats that promote inflammation, and its unique protein structure mimics a clot-dissolving molecule called plasminogen without actually dissolving clots. This means it competes with the real clot-dissolving system, promoting a state where blood clots form more easily and break down more slowly.
The risk from Lp(a) is independent of and additive to LDL cholesterol. In one analysis, people with elevated Lp(a) (50 mg/dL or higher) had an 83% higher risk of coronary heart disease events even when their LDL cholesterol was well controlled. This risk persists in people already taking cholesterol-lowering medications.
Heart Disease Without Major Blockages
Up to half of people who undergo imaging for chest pain or signs of reduced blood flow to the heart turn out to have no significant blockages in their large coronary arteries. Many of these patients have coronary microvascular dysfunction, a condition affecting the tiny blood vessels (smaller than 500 micrometers) that account for more than 70% of the resistance to blood flow in the heart.
In microvascular dysfunction, the small vessels undergo structural changes: their walls thicken from smooth muscle overgrowth, collagen builds up around them, and some capillaries disappear entirely. These changes reduce the heart’s ability to increase blood flow when demand rises, such as during exercise or stress. The result mimics the effect of a major blockage, producing chest pain and measurable ischemia, but standard angiograms look normal. Traditional risk factors like high blood pressure, diabetes, and high cholesterol all contribute to microvascular disease, and it carries real prognostic significance.
Detecting Disease Before Symptoms Appear
Because heart disease develops silently for decades, screening tools aim to catch it during the long buildup phase. One of the most useful is the coronary artery calcium (CAC) score, a quick CT scan that measures calcified plaque in the coronary arteries. The score is categorized into risk tiers: a score of zero indicates very low risk, 1 to 99 indicates mildly increased risk, 100 to 299 is moderately increased risk, and 300 or above signals moderate to severe risk. A score of zero is particularly reassuring because it means no calcified plaque is detectable, though it doesn’t completely rule out the presence of soft, non-calcified plaques.
The CAC score is most useful for people at intermediate risk, where the result can tip a treatment decision one way or the other. For someone already at high risk due to diabetes or very high cholesterol, or someone clearly at low risk, the scan adds less to the picture.